ILMN Quote, Financials, Valuation and Earnings

Guardant Health, Inc. has a net margin of 28.79% compared to Illumina, Inc.'s net margin of -34.97%. Illumina, Inc.'s return on equity of 35.12% beat Guardant Health, Inc.'s return on equity of -8518.58%.

Illumina, Inc. has a consensus price target of $135.84, signalling upside risk potential of 13.2%. On the other hand Guardant Health, Inc. has an analysts' consensus of $125.00 which suggests that it could grow by 17.5%. Given that Guardant Health, Inc. has higher upside potential than Illumina, Inc., analysts believe Guardant Health, Inc. is more attractive than Illumina, Inc..

Illumina, Inc. has a beta of 1.450, which suggesting that the stock is 44.964% more volatile than S&P 500. In comparison Guardant Health, Inc. has a beta of 1.631, suggesting its more volatile than the S&P 500 by 63.129%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Guardant Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. Guardant Health, Inc. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.2B, which are larger than Guardant Health, Inc. quarterly revenues of $265.2M. Illumina, Inc.'s net income of $334M is higher than Guardant Health, Inc.'s net income of -$92.7M. Notably, Illumina, Inc.'s price-to-earnings ratio is 21.96x while Guardant Health, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.31x versus 14.63x for Guardant Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Mettler-Toledo International, Inc. has a net margin of 28.79% compared to Illumina, Inc.'s net margin of 25.3%. Illumina, Inc.'s return on equity of 35.12% beat Mettler-Toledo International, Inc.'s return on equity of --.

Illumina, Inc. has a consensus price target of $135.84, signalling upside risk potential of 13.2%. On the other hand Mettler-Toledo International, Inc. has an analysts' consensus of $1,501.38 which suggests that it could grow by 9.07%. Given that Illumina, Inc. has higher upside potential than Mettler-Toledo International, Inc., analysts believe Illumina, Inc. is more attractive than Mettler-Toledo International, Inc..

Illumina, Inc. has a beta of 1.450, which suggesting that the stock is 44.964% more volatile than S&P 500. In comparison Mettler-Toledo International, Inc. has a beta of 1.424, suggesting its more volatile than the S&P 500 by 42.389%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mettler-Toledo International, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. Mettler-Toledo International, Inc. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.2B, which are larger than Mettler-Toledo International, Inc. quarterly revenues of $1.1B. Illumina, Inc.'s net income of $334M is higher than Mettler-Toledo International, Inc.'s net income of $285.8M. Notably, Illumina, Inc.'s price-to-earnings ratio is 21.96x while Mettler-Toledo International, Inc.'s PE ratio is 32.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.31x versus 7.07x for Mettler-Toledo International, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Natera, Inc. has a net margin of 28.79% compared to Illumina, Inc.'s net margin of -14.78%. Illumina, Inc.'s return on equity of 35.12% beat Natera, Inc.'s return on equity of -26.6%.

Illumina, Inc. has a consensus price target of $135.84, signalling upside risk potential of 13.2%. On the other hand Natera, Inc. has an analysts' consensus of $257.20 which suggests that it could grow by 18.88%. Given that Natera, Inc. has higher upside potential than Illumina, Inc., analysts believe Natera, Inc. is more attractive than Illumina, Inc..

Illumina, Inc. has a beta of 1.450, which suggesting that the stock is 44.964% more volatile than S&P 500. In comparison Natera, Inc. has a beta of 1.636, suggesting its more volatile than the S&P 500 by 63.611%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Natera, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. Natera, Inc. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.2B, which are larger than Natera, Inc. quarterly revenues of $592.2M. Illumina, Inc.'s net income of $334M is higher than Natera, Inc.'s net income of -$87.5M. Notably, Illumina, Inc.'s price-to-earnings ratio is 21.96x while Natera, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.31x versus 13.79x for Natera, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

GeneDx Holdings Corp. has a net margin of 28.79% compared to Illumina, Inc.'s net margin of -6.54%. Illumina, Inc.'s return on equity of 35.12% beat GeneDx Holdings Corp.'s return on equity of 0.82%.

Illumina, Inc. has a consensus price target of $135.84, signalling upside risk potential of 13.2%. On the other hand GeneDx Holdings Corp. has an analysts' consensus of $170.00 which suggests that it could grow by 87.47%. Given that GeneDx Holdings Corp. has higher upside potential than Illumina, Inc., analysts believe GeneDx Holdings Corp. is more attractive than Illumina, Inc..

Illumina, Inc. has a beta of 1.450, which suggesting that the stock is 44.964% more volatile than S&P 500. In comparison GeneDx Holdings Corp. has a beta of 2.078, suggesting its more volatile than the S&P 500 by 107.756%.

Illumina, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeneDx Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Illumina, Inc. pays -- of its earnings as a dividend. GeneDx Holdings Corp. pays out -- of its earnings as a dividend.

Illumina, Inc. quarterly revenues are $1.2B, which are larger than GeneDx Holdings Corp. quarterly revenues of $116.7M. Illumina, Inc.'s net income of $334M is higher than GeneDx Holdings Corp.'s net income of -$7.6M. Notably, Illumina, Inc.'s price-to-earnings ratio is 21.96x while GeneDx Holdings Corp.'s PE ratio is 1,503.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Illumina, Inc. is 4.31x versus 6.47x for GeneDx Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.